rvsvdg-zebov-gp
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started Jan 15, 2024 (NCT05992480)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- EbolavirusImmunity, active
Ebolavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06587503 | Phase 4 | Oct 31, 2024 | Merck, Rwanda Biomedical Centre, University of Birmingham |
| NCT05992480 | Phase 4 | Jan 15, 2024 | Merck, Tulane University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 0 | 1 | 2024 |
| Rwanda Biomedical Centre | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Tulane University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Birmingham | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1